Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 30 2018 - 6:00PM
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage
biopharmaceutical company focused on the discovery and development
of precision genetic medicine to treat rare neuromuscular diseases,
granted equity awards on March 30, 2018, that were previously
approved by the Compensation Committee of its Board of Directors
under Sarepta’s 2014 Employment Commencement Incentive Plan, as a
material inducement to employment to twelve individuals hired by
Sarepta in March 2018. The equity awards were approved in
accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received, in the aggregate, options to purchase
42,443 shares of Sarepta's common stock. The options have an
exercise price of $74.09 per share. One-fourth of the shares
underlying each employee’s option will vest on the one year
anniversary of his or her date of hire and thereafter 1/48th of the
shares underlying each employee’s option will vest monthly, such
that the shares underlying the option granted to each employee will
be fully vested on the fourth anniversary of his or her date of
hire, in each case, subject to each such employee’s continued
employment with Sarepta on such vesting dates.
About Sarepta TherapeuticsSarepta
Therapeutics is a commercial-stage biopharmaceutical company
focused on the discovery and development of precision genetic
medicine to treat rare neuromuscular diseases. The Company is
primarily focused on rapidly advancing the development of its
potentially disease-modifying Duchenne muscular dystrophy (DMD)
drug candidates. For more information, please visit
www.sarepta.com.
Internet Posting of InformationWe routinely
post information that may be important to investors in the 'For
Investors' section of our website at www.sarepta.com. We
encourage investors and potential investors to consult our website
regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors: Sarepta Therapeutics, Inc. Ian Estepan,
617-274-4052 iestepan@sarepta.com or W2O Group Brian Reid,
212-257-6725 breid@w2ogroup.com
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Sep 2023 to Sep 2024